Sorrento Therapeutics, Inc. (SRNEQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sorrento Therapeutics, Inc. (SRNEQ) trades at $0.03 with AI Score 49/100 (Grade C). Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company focused on developing treatments for cancer, infectious diseases, and pain. Market cap: $16.5M, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for SRNEQ: SRNEQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SRNEQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SRNEQ: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Sorrento Therapeutics, Inc. (SRNEQ) Healthcare & Pipeline Overview
Sorrento Therapeutics, Inc. is a biopharmaceutical company developing next-generation therapies for cancer, infectious diseases, and pain, leveraging its G-MAB antibody library and targeted delivery modalities. Currently operating under Chapter 11 reorganization, Sorrento focuses on CAR-T therapies, pain management solutions, and lymphatic drug delivery, competing in the biotechnology sector.
What Is the Investment Thesis for SRNEQ?
Sorrento Therapeutics faces significant challenges due to its Chapter 11 reorganization filing in February 2023. The company's diverse pipeline, including CAR-T therapies and pain management solutions like resiniferatoxin and ZTlido, represents potential long-term value. However, the bankruptcy proceedings introduce substantial uncertainty and risk. The company's ability to successfully navigate the reorganization, secure funding, and advance its clinical programs will be critical for future growth. Investors should closely monitor the progress of the Chapter 11 case and clinical trial outcomes. The company's negative profit margin of -911.6% and current market capitalization of $16.5M reflect the financial strain.
Based on FMP financials and quantitative analysis
SRNEQ Key Highlights
Sorrento Therapeutics filed for Chapter 11 reorganization on February 13, 2023, introducing financial uncertainty.
- The company's pipeline includes CAR-T therapies for multiple myeloma, amyloidosis, and graft versus host disease.
- Resiniferatoxin, a non-opioid TRPV1 agonist, is being developed for late-stage cancer and osteoarthritis pain.
- ZTlido, a lidocaine topical system, is available for the treatment of post-herpetic neuralgia.
- The company's gross margin is 46.8%.
Who Are SRNEQ's Competitors?
SRNEQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMHV American Hemp Ventures, Inc. | $0.98 | +0.00% | $16.5M | 46 |
| CRPOF Ceapro Inc. | $0.17 | -13.04% | $13.3M | 46 |
| EIGRQ Eiger BioPharmaceuticals, Inc. | $8.50 | +6.25% | $12.6M | 54 |
| EMMLF OKYO Pharma Limited | $0.01 | +0.00% | $22.7M | 44 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +5.06% | $7.16M | 72 |
| RLYB Rallybio Corporation | $17.00 | +1.37% | $90.2M | 81 |
| ICCC ImmuCell Corporation | $10.13 | +3.79% | $91.6M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SRNEQ's Key Strengths?
Proprietary G-MAB antibody library.
- Innovative drug delivery technologies (Sofusa).
- Diverse pipeline of clinical-stage drug candidates.
- Strategic collaborations with Mayo Clinic and SmartPharm Therapeutics.
What Are SRNEQ's Weaknesses?
Chapter 11 reorganization filing.
- Negative profit margin (-911.6%).
- Limited financial resources.
- Dependence on successful clinical trial outcomes.
What Could Drive SRNEQ Stock Higher?
Data readouts from ongoing clinical trials for CAR-T therapies.
- Potential regulatory submissions for resiniferatoxin (RTX) for pain management.
- Progress in Chapter 11 reorganization proceedings.
- Development and expansion of Sofusa lymphatic drug delivery technology.
- Advancement of SEMDEXA clinical trials for sciatica treatment.
What Are the Key Risks for SRNEQ?
Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
- Uncertainty related to Chapter 11 reorganization and potential outcomes.
- Failure to secure regulatory approvals for key drug candidates.
- Competition from established pharmaceutical companies and other biotech firms.
- Patent challenges and intellectual property disputes.
- Limited financial resources and dependence on external funding.
What Are the Growth Opportunities for SRNEQ?
- CAR-T Therapy Development: Sorrento's anti-CD38 CAR-T therapy program represents a significant growth opportunity in the treatment of multiple myeloma, amyloidosis, and graft versus host disease. Successful clinical trials and regulatory approvals could position Sorrento as a key player in this rapidly expanding market. Timeline: Ongoing clinical trials with potential for data readouts in the next 1-2 years.
- Pain Management Solutions: The development and commercialization of resiniferatoxin (RTX) for late-stage cancer and osteoarthritis pain offers a substantial growth opportunity. The global pain management market is estimated to reach $83 billion by 2027. RTX's non-opioid mechanism of action addresses the growing need for safer and more effective pain relief options. Timeline: Ongoing clinical trials with potential for regulatory submissions in the next 2-3 years.
- Sofusa Lymphatic Drug Delivery Technology: Sorrento's Sofusa technology has the potential to enhance the efficacy and safety of biologic drugs by delivering them directly into the lymphatic system. This technology can be applied to a wide range of therapeutic areas, including cancer, autoimmune diseases, and infectious diseases. The lymphatic drug delivery market is expected to grow significantly in the coming years. Sorrento's collaboration with Mayo Clinic to deliver Ipilimumab in melanoma patients highlights the potential of this technology. Timeline: Ongoing Phase Ib pilot study with potential for expansion into other indications.
- SEMDEXA for Sciatica: SEMDEXA, an injectable viscous gel formulation in Phase III trials for sciatica, represents a significant market opportunity. Sciatica affects a large population, and effective non-surgical treatments are in high demand. Positive trial results and regulatory approval could lead to substantial revenue generation. Timeline: Phase III trial ongoing, with potential for data readout and regulatory submission within the next 1-2 years.
- COVID-19 Antibody Vaccine: Sorrento's collaboration with SmartPharm Therapeutics Inc. to develop a gene-encoded antibody vaccine against COVID-19 presents a growth opportunity, although the urgency has decreased. While the initial surge in demand for COVID-19 vaccines has subsided, there remains a need for variant-specific boosters and alternative vaccine technologies. Timeline: Ongoing development with potential for clinical trials in the next year.
What Are SRNEQ's Competitive Advantages?
- Proprietary G-MAB antibody library for antibody discovery.
- Sofusa technology for targeted lymphatic drug delivery.
- Patent protection for its drug candidates and technologies.
- Clinical trial data demonstrating the safety and efficacy of its products.
- Strategic partnerships with leading research institutions and pharmaceutical companies.
What Does SRNEQ Do?
Founded in 2006 and based in San Diego, California, Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company dedicated to the development of innovative treatments across three major therapeutic areas: cancer, infectious diseases, and pain management. The company operates through two segments, Sorrento Therapeutics and Scilex. Sorrento leverages its proprietary G-MAB antibody library and targeted delivery modalities, including CAR-T cell therapy, dimeric antigen receptor T-cell therapy, antibody-drug conjugates, and bispecific antibody approaches. Its Sofusa technology delivers biologics directly into the lymphatic system. Sorrento's clinical programs include anti-CD38 CAR-T therapy for multiple myeloma, amyloidosis, and graft versus host disease. The company is also developing resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin, for late-stage cancer and osteoarthritis pain, and ZTlido, a lidocaine topical system for post-herpetic neuralgia. Additional pipeline products include SEMDEXA, an injectable gel for sciatica, SP-103 for chronic low back pain, and SP-104 for fibromyalgia. Sorrento has a collaboration with SmartPharm Therapeutics Inc. for a gene-encoded antibody vaccine against COVID-19 and with Mayo Clinic for a Phase Ib study using Sofusa to deliver Ipilimumab in melanoma patients. On February 13, 2023, Sorrento and its affiliate filed for Chapter 11 reorganization.
What Products and Services Does SRNEQ Offer?
- Develops CAR-T cell therapies for cancer treatment.
- Creates antibody-drug conjugates for targeted cancer therapy.
- Develops bispecific antibodies for cancer immunotherapy.
- Utilizes Sofusa technology for lymphatic drug delivery.
- Develops non-opioid pain management solutions like resiniferatoxin.
- Offers ZTlido, a lidocaine topical system for post-herpetic neuralgia.
- Develops SEMDEXA for the treatment of sciatica.
- Researches and develops treatments for infectious diseases.
How Does SRNEQ Make Money?
- Develops and patents novel therapeutic technologies.
- Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Seeks regulatory approvals from agencies like the FDA.
- Commercializes approved products directly or through partnerships.
- Generates revenue through product sales, licensing agreements, and collaborations.
What Industry Does SRNEQ Operate In?
Sorrento Therapeutics operates within the competitive biotechnology industry, characterized by high research and development costs, lengthy clinical trial processes, and regulatory hurdles. The market for cancer therapies, pain management solutions, and infectious disease treatments is substantial and growing, driven by an aging population and increasing prevalence of chronic diseases. Sorrento competes with established pharmaceutical companies and other biotech firms, including AMHV, AVEFF, CRPOF, EIGRQ, and EMMLF, in developing and commercializing innovative therapies. The company's success depends on its ability to secure regulatory approvals, protect its intellectual property, and establish strategic partnerships.
Who Are SRNEQ's Key Customers?
- Patients suffering from cancer, infectious diseases, and chronic pain.
- Hospitals and clinics that administer Sorrento's therapies.
- Pharmaceutical companies that partner with Sorrento for drug development and commercialization.
- Research institutions that collaborate with Sorrento on scientific studies.
- Healthcare providers prescribing Sorrento's products.
How Sorrento Therapeutics, Inc. Is Valued
Sorrento Therapeutics, Inc. carries a market capitalization of $16.5M, placing it in the micro-cap category. Relative to its peer group, SRNEQ's quantitative score of 49/100 is roughly in line with the peer average of 52/100.
Company Profile
Sorrento Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Henry H. Ji. SRNEQ has traded publicly since 2007.
Earnings Track Record
Sorrento Therapeutics, Inc. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 79.4% below estimates on average.
SRNEQ Financials
Bull Case vs Bear Case
Bull Case
- Proprietary G-MAB antibody library.
- Innovative drug delivery technologies (Sofusa).
- Diverse pipeline of clinical-stage drug candidates.
- Strategic collaborations with Mayo Clinic and SmartPharm Therapeutics.
Bear Case
- Chapter 11 reorganization filing.
- Negative profit margin (-911.6%).
- Limited financial resources.
- Dependence on successful clinical trial outcomes.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
SRNEQ Latest News
No recent news available for SRNEQ.
SRNEQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SRNEQ.
Price Targets
Wall Street price target analysis for SRNEQ.
SRNEQ MoonshotScore
What does this score mean?
The MoonshotScore rates SRNEQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Henry H. Ji
CEO
Henry H. Ji serves as the CEO of Sorrento Therapeutics, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on developing and commercializing innovative therapies. He has led Sorrento through various stages of growth and development, overseeing the expansion of its pipeline and the establishment of strategic partnerships. His expertise spans drug discovery, clinical development, and regulatory affairs.
Track Record: Under Henry Ji's leadership, Sorrento Therapeutics has advanced multiple drug candidates into clinical trials and secured regulatory approvals for products like ZTlido. He has also overseen the company's strategic collaborations with leading research institutions and pharmaceutical companies. However, the recent Chapter 11 filing represents a significant challenge during his tenure.
SRNEQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Sorrento Therapeutics (SRNEQ) may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, are in financial distress, or may not be current in their reporting obligations. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and transparency compared to exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited regulatory oversight and disclosure requirements.
- Higher risk of fraud and manipulation.
- Potential for delisting and loss of investment.
- Limited liquidity and trading volume.
- Increased price volatility.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Monitor news and press releases for updates on the company's financial condition and operations.
- Consult with a qualified financial advisor before investing.
- Established history of operations since 2006.
- Development of multiple clinical-stage drug candidates.
- Strategic collaborations with reputable institutions like Mayo Clinic.
- Patent portfolio protecting its technologies and drug candidates.
- Presence of a CEO and management team.
Sorrento Therapeutics, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for SRNEQ?
SRNEQ holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company focused on developing treatments for cancer, infectious diseases, and pain. The company filed for Chapter 11 …
What does Sorrento Therapeutics, Inc. do?
Sorrento Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for cancer, pain, and infectious diseases. The company leverages its proprietary G-MAB antibody library and targeted delivery modalities, including CAR-T cell therapy and Sofusa lymphatic drug delivery technology, to create next-generation treatments. Sorrento's pipeline includes clinical-stage drug candidates for multiple myeloma, osteoarthritis pain, sciatica, and COVID-19.
What are the main risks for SRNEQ?
The primary risk for Sorrento Therapeutics is the uncertainty surrounding its Chapter 11 reorganization. The outcome of the bankruptcy proceedings could significantly impact the value of the company's stock and its ability to continue operations. Other risks include the potential failure of clinical trials, regulatory hurdles, competition from other pharmaceutical companies, patent challenges, and limited financial resources. Investors should carefully consider these risks before investing in SRNEQ.
What are the key factors to evaluate for SRNEQ?
Sorrento Therapeutics, Inc. (SRNEQ) holds an AI score of 49/100 (low). Sorrento Therapeutics faces significant challenges due to its Chapter 11 reorganization filing in February 2023. Not financial advice.
How frequently does SRNEQ data refresh on this page?
SRNEQ's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SRNEQ's recent stock price performance?
Sorrento Therapeutics, Inc. (SRNEQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary G-MAB antibody library. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SRNEQ overvalued or undervalued right now?
Sorrento Therapeutics, Inc. (SRNEQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SRNEQ before investing?
Before investing in Sorrento Therapeutics, Inc. (SRNEQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SRNEQ to a portfolio?
Key strength of Sorrento Therapeutics, Inc. (SRNEQ): Proprietary G-MAB antibody library. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- The company is currently undergoing Chapter 11 reorganization, which introduces significant uncertainty.